There is limited literature available that specifically evaluates the use of prophylaxis with BPA prior to or while patients are receiving ITI and to the authors’ best knowledge, no comparative trials of bypassing agents used as prophylaxis in patients with Haemophilia A and inhibitors to FVIII are currently available in the literature. This evidence concerns the gene F8 and hemophilia A.